Co-Diagnostics, Inc. Q3 2025 Earnings Recap

CODX Q3 2025 November 15, 2025

Get alerts when CODX reports next quarter

Co-Diagnostics reported significant progress in Q3 2025, highlighting strategic partnerships and initiatives aimed at enhancing operational capabilities and expanding its international footprint.

Earnings Per Share Beat

$-4.80 vs $-5.71 est.

+15.9% surprise

Revenue Beat

145380 vs 126000 est.

+15.4% surprise

Market Reaction

1-Day +13.61%

5-Day +5.7%

30-Day -12.66%

See CODX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Initiation of a SPAC transaction potentially unlocking substantial value from the CoSara Diagnostics joint venture in India.
Launch of CoMira joint venture with Arabian Eagle to localize and distribute the Co-Dx PCR platform across 19 countries in the MENA region.
Focus on innovation through its AI business unit, enhancing operational efficiency and opening new market opportunities.
The company is poised for growth with strategic financial maneuvers aimed at solidifying its balance sheet as it prepares for commercialization in 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CODX on AllInvestView.

Next Q1 2026